Long‑responders to anti‑HER2 therapies: Aï¿½caseï¿½report and review of the literature-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Long‑responders to anti‑HER2 therapies: Aï¿½caseï¿½report and review of the literature

Published:2017-11-08 Issue: Volume: Page:
ISSN:2049-9450
Container-title:Molecular and Clinical Oncology
language:
Short-container-title:mol clin onc

Author:

Cantini Luca¹,Pistelli Mirco¹,Savini Agnese¹,Bastianelli Lucia¹,Della Mora Arianna¹,Merloni Filippo¹,Burattini Michela¹,Berardi Rossana¹

Affiliation:

1. Medical Oncology, Marche Polytechnic University, University Hospital Ospedali Riuniti Ancona, I-60126 Ancona, Italy

Publisher

Spandidos Publications

Subject

Cancer Research,Oncology

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-Term Survival in Human Epidermal Growth Factor Receptor 2-Positive Bone-Only Metastatic Breast Cancer: Trastuzumab, Denosumab, and Potential Synergistic Effects;Cureus;2024-09-03

2. Clinico-pathological predictors of radiologic complete response to first-line anti-HER2 therapy in metastatic breast cancer: insights from real-world data of a nationwide cohort;2024-05-15

3. A Case Report on Prolonged Response with Trastuzumab Emtansine (T-DM1) in Recurrent Advance Breast Cancer Setting;Journal of Cancer Research Updates;2023-12-11

4. Trastuzumab therapy duration in HER2-positive de novo metastatic breast cancer: 1999–2018;Breast Cancer Research and Treatment;2022-07-22

5. Crosstalk between HER2 and PD-1/PD-L1 in Breast Cancer: From Clinical Applications to Mathematical Models;Cancers;2020-03-10

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP